Evidence map›Paper›PMID 33915693›Full record

ArticleCancers2021

Efficacy and Safety of Checkpoint Inhibitor Treatment in Patients with Advanced Renal or Urothelial Cell Carcinoma and Concomitant Chronic Kidney Disease: A Retrospective Cohort Study.

Florian Seydel, Susanne Delecluse, Martin Zeier, Tim Holland-Letz, Georg Martin Haag, Anne Katrin Berger, Barbara Christine Grün, Nina Bougatf, Markus Hohenfellner, Stefan Duensing and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 1 country.

Florian SeydelDepartment of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Susanne DelecluseDepartment of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Martin ZeierDepartment of Nephrology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Tim Holland-LetzGerman Cancer Research Centre (DKFZ) Unit C060, 69120 Heidelberg, Germany.
Georg Martin HaagDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
Anne Katrin BergerDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
Barbara Christine GrünDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
Nina BougatfCancer Registry, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.ORCID 0000-0002-0718-7360
Markus HohenfellnerDepartment of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Stefan DuensingDepartment of Urology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Dirk JägerDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
Stefanie ZschäbitzDepartment of Medical Oncology, National Center of Tumor Diseases (NCT), University Hospital Heidelberg, 69120 Heidelberg, Germany.
Heidelberg University · DEGerman Cancer Research Center · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

checkpoint inhibitorchronic kidney diseaserenal cell carcinomaurothelial carcinoma

Identifiers

PMID33915693
PMCPMC8036307
OpenAlexW3150550899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.